In a phase II study of HER2-positive primary inflammatory breast cancer patients, the prevalences of patients with one or more CTCs and five or more CTCs were 35% and 13%, respectively, and lower compared with our study, which includes HER2-negative patients as well [36]; unfortunately, we are not aware of any data on CTC prevalence in patients with newly diagnosed locally advanced non-IBC, a more appropriate group for comparison with our patients with stage III IBC. This evidence concerns the gene ERBB2 and breast carcinoma.